A phase III, open-label, prospective, two-armed, multicenter, randomized, group sequential study to evaluate the efficacy and safety of subsequent treatment with the Zevalin (ibritumomab tiuxetan) [ibritumomab tiuxetan Y-90] study regimen versus observation in patients with diffuse large B-cell lymphoma who are in complete remission after first-line CHOP-rituximab (CHOP-R) [cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab] therapy

Trial Profile

A phase III, open-label, prospective, two-armed, multicenter, randomized, group sequential study to evaluate the efficacy and safety of subsequent treatment with the Zevalin (ibritumomab tiuxetan) [ibritumomab tiuxetan Y-90] study regimen versus observation in patients with diffuse large B-cell lymphoma who are in complete remission after first-line CHOP-rituximab (CHOP-R) [cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab] therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Ibritumomab tiuxetan (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ZEAL
  • Sponsors Biogen; Cell Therapeutics; CTI BioPharma
  • Most Recent Events

    • 14 Jul 2009 Bayer added as trial sponsor as reported by ClinicalTrials.gov.
    • 22 Oct 2008 Added Cell Therapeutics as an affiliate and sponsor, from clinicaltrials.gov.
    • 22 Oct 2008 Status changed from recruiting to active, no longer recruiting, according to clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top